<DOC>
	<DOCNO>NCT00078598</DOCNO>
	<brief_summary>A total 506 patient , 253 per arm , enrol 30 40 site United States Europe . Patients randomly assign one two treatment arm . In Arm A , patient receive 375 mg/m2 rituximab ( US , Canada – Rituxan® ; EU - Mabthera® ) , give IV infusion weekly 4 week . In Arm B , patient receive Iodine I 131 Tositumomab therapy . For Arm B , patient undergo two-phase treatment . In first phase , term “ dosimetric dose , ” patient receive infusion unlabeled Tositumomab ( 450 mg ) immediately follow infusion Tositumomab ( 35 mg ) label 5 mCi ( 0.18 GBq ) iodine 131 . Whole body gamma camera scan obtain three time ( Day 0 , Day 2 , 3 , 4 , Day 6 7 ) follow dosimetric dose . Using dosimetric data three image timepoints , patient ’ weight , platelet count , patient-specific administered activity iodine I 131 Tositumomab ( express mCi GBq ) calculate deliver desire total body dose radiation ( 65 75 cGy ) . In second phase , term “ therapeutic dose , ” patient Arm B receive infusion unlabeled Tositumomab ( 450 mg ) immediately follow infusion patient-specific administer activity Iodine 131–conjugated Tositumomab ( 35 mg ) . Patients study follow response safety Week 7 , Week 13 , every 3 month first second year , every 6 month third year , annually fourth fifth year . Patients follow safety annually year 6-10 .</brief_summary>
	<brief_title>A Study Rituximab Versus Iodine I 131 Tositumomab Therapy Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Inclusion Criteria A histologically confirm diagnosis follicular lymphoma , Grade I , II , III ( WHO/REAL Classification ) ( follicular , small cleave ; follicular , mixed smallcleaved largecell ; follicular largecell lymphoma International Working Formulation ) . Recurrent lymphoma one two qualify therapy regimen ( ) . A performance status least 70 % Karnofsky Scale . An absolute neutrophil count &gt; 1500 cells/mm3 platelet count &gt; 100,000 cells/mm3 . Adequate renal function adequate hepatic function . Bidimensionally measurable disease least one lesion measure &gt; equal 2.0 x 2.0 cm ( i.e. , &gt; 4.0 cm2 ) CT scan . HAMA negative . At least 18 year age . Give write informed consent sign IRB/ethics committee approve informed consent form prior study entry . Exclusion Criteria Histological transformation diffuse , large cell lymphoma More 1 course rituximab Disease well treat limited field therapy Involvement &gt; 25 % intratrabecular marrow Active infection Significant cardiac disease Prior ChemoRx , biological therapy , radiation Rx , high dose systemic steroid therapy within 8 week Prior radioimmunotherapy History another malignancy HBsAg positivity CNS involvement lymphoma Pregnant nursing Ascites physical exam Previous use nonhuman monoclonal antibody therapy , know hypersensitive murine protein Hydronephrosis Radiotherapy &gt; 25 % blood forming marrow Prior stem cell transplant Failed stem cell harvest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Follicular</keyword>
</DOC>